Alzheimer's
Partial Reprogramming vs. Alzheimer's
The video below contains key highlights of latest research results, including those of YouthBio, investigating therapeutic benefits of partial reprogramming of the brain in animal models of Alzheimer’s, memory loss, cognitive decline, adult neurogenesis etc.:

Key Scientific Publications:


Alzheimer's:


“controlled [Yamanaka factors] induction … prevented the development of several hallmarks of Alzheimer’s disease, including cognitive decline and altered molecular signatures, in the 5xFAD mouse model [of Alzheimer’s Disease]”

“Furthermore, the in vivo methylation of APP in the brain via dCas9-Dnmt3a treatment altered Aβ plaques and attenuated cognitive and behavioral impairments in the APP-KI mouse model”

“These findings suggest that Alzheimer's Disease involves a reconfiguration of the epigenomic landscape, with the marks H3K27ac and H3K9ac affecting disease pathways by disrupting transcription- and chromatin-gene feedback loops. The identification of this process highlights potential strategies to modulate these marks for early-stage disease treatment.”

“controlled [Yamanaka factors] induction … prevented the development of several hallmarks of Alzheimer’s disease, including cognitive decline and altered molecular signatures, in the 5xFAD mouse model [of Alzheimer’s Disease]”



Other Brain Partial Reprogramming Results:



“Importantly, partial reprogramming improves the production of new neurons in vitro and in old brains. Our work suggests that partial reprogramming could be used to rejuvenate the neurogenic niche and counter brain decline in old individuals.”

“In summary, the administration of Yamanaka genes via viral vectors rejuvenates the functional capabilities and the epigenetic landscape of the rat hippocampus.”

“We conclude that transient cyclic reprogramming in vivo in the central nervous system could be an effective strategy to ameliorate aging of the central nervous system and neurodegenerative diseases”

“The particular significance of the present results is that, for the first time, they show that long-term OSKM gene therapy in the hypothalamus is able to extend the functionality of such a complex system as the hypothalamo-pituitary-ovarian axis.”